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INTRODUCTION
Therapies using targeted monoclonal antibodies have proven safe 
and effective against hematologic malignancies.1 In particular, ritux-
imab, which targets the B-cell marker CD20, has greatly enhanced 
outcomes in patients with non-Hodgkin’s lymphoma or chronic 
lymphocytic leukemia. However, not all patients respond to ritux-
imab, and many of those who do eventually experience disease 
relapse.2–5 Monoclonal antibody therapies directed against other 
B-cell antigens, such as CD19, CD22, CD30, CD37, CD40, or CD52, are 
in development at different stages of preclinical/clinical testing.5–11 
B-cell–targeted therapies with novel mechanisms of action are still 
necessary in order to improve cure rates, and innovative  therapies 
could prove cost-effective in the treatment of  hematologic 
malignancies.12
Existing monoclonal antibody therapies rely on the action of 
complement-dependent cytotoxicity and antibody-dependent 
cell-mediated cytotoxicity,13,14 or utilize a conjugated toxin or radio-
labeled isotope.13 Other strategies harness the ability of cytotoxic T 
lymphocytes (CTLs) to kill target cells, relying on ex vivo manipula-
tion to expand tumor-specific CTLs15 or to express chimeric antigen 
receptors16; but these approaches are limited by major histocom-
patibility (MHC) restriction in tumor-specific CTLs, as well as scal-
ability and risks involved.17
Recently, the development of bispecific T-cell-redirecting 
 antibody-derived molecules has made possible treatment strat-
egies that bypass the requirement for MHC matching or ex vivo 
manipulation and expansion of CTLs. These bispecific molecules 
bind simultaneously to a receptor on T cells and to a specific antigen 
on a target cell, thus redirecting T cells to kill the target cells. One 
example is blinatumomab, a bispecific T cell engager (BiTE) mol-
ecule targeting CD19, which demonstrated complete responses in 
72% of patients with persistent or relapsed minimal residual disease 
and a median overall survival of 9 months.18
To build upon this success, newer generations of bispecific mol-
ecules have been developed, like the dual-affinity re-targeting 
(DART) molecules. DART molecules differ from BiTE molecules in 
two ways: there is no intervening linker sequence between the V 
regions of DART molecules, and there are two cysteine residues at 
the C-terminus of each chain which form a disulfide bridge.19,20 In a 
previous report comparing DART molecules with BiTE molecules, 
DART molecules seemed to perform better than BiTE molecules with 
respect to antigen binding, ability to crosslink target/effector cells, 
induction of T-cell activation markers, EC50 for target cell lysis, and 
maximal target cell lysis.20,21 A CD123xCD3 DART protein (directed 
against human CD3 and human CD123) was active against human 
AML cell line engraftments in NSG/β2m-/- mice reconstituted with 
human peripheral blood mononuclear cells (PBMCs), and, due to its 
crossreactivity to both antigens from cynomolgus monkeys, depleted 
CD123+ cells when administered to the monkeys.22 A CD19xTCR DART 
protein (directed against human CD19 and human T-cell receptor αβ 
subunit) was active against human B-cell lymphoma xenografts in 
NOD/SCID mice reconstituted with human PBMCs.20 A CD19xCD3 
DART protein in an extended half-life format was active against B-cell 
lymphoma xenografts in mice reconstituted with human PBMCs, and, 
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Novel therapeutic strategies are needed for the treatment of hematologic malignancies; and bispecific antibody-derived mol-
ecules, such as dual-affinity re-targeting (DART) proteins, are being developed to redirect T cells to kill target cells expressing tumor 
or viral antigens. Here we present our findings of specific and systemic human B-cell depletion by a CD19xCD3 DART protein in 
humanized BLT mice. Administration of the CD19xCD3 DART protein resulted in a dramatic sustained depletion of human CD19+ B 
cells from the peripheral blood, as well as a dramatic systemic reduction of human CD19+ B-cell levels in all tissues (bone marrow, 
spleen, liver, lung) analyzed. When human CD8+ T cells were depleted from the mice, no significant B-cell depletion was observed 
in response to CD19xCD3 DART protein treatment, confirming that human CD8+ T cells are the primary effector cells in this in vivo 
model. These studies validate the use of BLT humanized mice for the in vivo evaluation and preclinical development of bispecific 
molecules that redirect human T cells to selectively deplete target cells.
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due to its crossreactivity to both antigens from cynomolgus monkeys, 
depleted CD19+ B cells in peripheral blood and lymph nodes when 
administered to the monkeys.23 However, there has yet to be a sys-
temic in vivo evaluation of the effect of CD19xCD3 DART molecules 
on human immune cells generated de novo from hematopoietic stem 
cells.
Bone marrow–liver–thymus (BLT) humanized mice could serve as 
an excellent preclinical model for the in vivo evaluation of CD19xCD3 
DART molecules. BLT mice are generated by implanting human thy-
mus and liver tissue into sublethally irradiated NOD/SCID-γ  chain 
null mice, followed by transplanting autologous human CD34+ 
hematopoietic stem cells.24,25 BLT mice develop robust levels of 
human hematopoietic cells throughout the body, including T cells, 
B cells, monocytes/macrophages, and dendritic cells26; and this 
model has been utilized in the study of B cells, immune reconstitu-
tion, and HIV infection.27–37
In this manuscript, we evaluated the efficacy of human B-cell 
depletion by a CD19xCD3 DART protein, in which the binding 
arms are equivalent to those utilized in blinatumomab,21,38 in BLT 
humanized mice. Our results demonstrate that this DART molecule 
is effective at depleting human B cells in peripheral blood and tis-
sues. We also show that this effect occurred on mature B cells and 
that progenitor cells remain functionally capable of generating new 
human B cells in the bone marrow. Finally, we demonstrate that 
B-cell depletion by this CD19xCD3 DART molecule is dependent on 
human CD8+ T cells. Together, our results provide in vivo evidence 
of the functional capacity of T-cell–redirecting DART proteins and 
validate the utilization of the BLT humanized mouse model for the 
preclinical evaluation of these molecules.
ReSUlTS
Depletion of human CD19+ B cells in peripheral blood after 
administration of CD19xCD3 DART protein
In order to evaluate the efficacy of CD19xCD3 DART proteins to 
deplete human B cells in vivo, we utilized BLT humanized mice. BLT 
mice were constructed as previously described.32 The mice used 
for all experiments were 16–20 weeks post humanization proce-
dure, and they were well reconstituted with human CD45+ cells 
(63.5% ± 13.6 SD). Of the human CD45+ cells present in peripheral 
blood at the beginning of the experiments, 39% ± 9.3 SD expressed 
human CD19, and 53.3% ± 10.7 SD expressed CD3 on their cell sur-
face. 78.3%  ±  6.5 SD of human CD3+ cells expressed human CD4 
(data not shown).
For our experiments, we used a CD19xCD3 DART molecule in which 
the CD19 arm was derived from anti-human CD19 antibody HD37, 
and the CD3 arm was derived from anti-human CD3 antibody TR66, 
as described by Moore et al.20; these binding arms are equivalent to 
those of blinatumomab.38 This bispecific molecule binds to human 
CD3 on T cells and to human CD19 on B cells, and it recruits the cyto-
toxic activity of the T cells to kill the target B cells. The CD19xCD3 
DART molecule was administered to BLT mice (n = 3) i.v. (1 mg/kg) in 
two doses, 7 days apart. A similar group of BLT mice was administered 
vehicle (normal saline, n = 3). Peripheral blood was collected for flow 
cytometric analysis on days 0, 1, 3, 7, and 11 after the first injection 
(Figure 1a, gating scheme in Supplementary Figure S1a).
Initially after CD19xCD3 DART molecule administration (day 1), 
the levels of total human CD45+ cells detected from the peripheral 
blood dropped to 3.2% ± 1.3 SEM (or 38 ± 11 CD45+ cells per micro-
liter of blood); but this decrease was transient, as the levels of CD45+ 
cells returned to approximately normal levels by day 3 (Figure 1b,c). 
With regard to the target human CD19+ B cells, the pretreatment 
Figure 1 CD19xCD3 DART protein administration depletes human CD19+ 
B cells from the peripheral blood. (a) Experimental outline. NSG/BLT mice 
were administered CD19xCD3 (n = 3, 1 mg/kg i.v.) or vehicle (n = 3) at day 
0 and day 7. Peripheral blood (PB) was collected and analyzed at days 0, 1, 
3, 7, 11. (b) Percent CD45+ cells out of live cells and (c) number CD45+ cells 
per microliter detected in PB by flow cytometry (vehicle group in blue, 
CD19xCD3 group in red). (d) Percent CD19+ cells out of CD45+ cells and 
(e) number CD19+ cells per microliter detected in PB by flow cytometry 
(open circle = below limit of quantitation). (Mean ± SEM plotted. P values 
were calculated by repeated-measures two-way analysis of variance with 
Sidak’s multiple comparisons test, comparing vehicle versus CD19xCD3. 
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Figure 2 CD19xCD3 DART protein administration depletes human CD19+ 
B cells from the tissues. NSG/BLT mice were administered CD19xCD3 
(n = 3, 1 mg/kg intravenously) or vehicle (n = 3) at day 0 and day 7. 
Tissues were harvested and analyzed at day 11. (a) Percent CD19+ cells 
out of CD45+ cells and (b) number CD19+ cells detected in tissues by flow 
cytometry (vehicle group in blue; CD19xCD3 group in red). (Mean ± SEM 
plotted. P values were calculated by unpaired t-test, comparing 
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(day 0) levels of CD19+ cells in peripheral blood were 27.8% ± 1.5 
CD19+ out of CD45+. By day 1 after CD19xCD3 administration, the 
percentage of CD19+ cells out of CD45+ cells fell to below limit of 
quantitation by flow cytometry. The levels of CD19+ cells in the 
peripheral blood remained lower than 0.1% on days 3, 7, and 11 
after CD19xCD3 administration (Figure 1d). This decrease in human 
CD19+ B cells was also reflected in the absolute numbers of cells. 
Specifically, the number of CD19+ cells per microliter in the periph-
eral blood of the CD19xCD3-treated animals was reduced from 
413 ± 67 CD19+ cells per microliter to <1 CD19+ cell per microliter 
of blood (Figure 1e).
In contrast to the extensive decreases in the levels of human CD19+ 
B cells in the CD19xCD3-treated mice, the animals treated with 
vehicle maintained relatively high levels of CD19+ cells. It should be 
noted that the decrease observed in percentage of human CD19+ 
cells out of CD45+ cells is consistent with the increases in human 
T-cell reconstitution that occur over time in this animal model 
(Supplementary Figure S2). However, the number of human CD19+ 
cells per microliter did not change significantly between day 0 and 
day 11 in the animals receiving vehicle (Figure 1e). All differences in 
the levels of human B cells between the CD19xCD3 group and the 
vehicle group were statistically significant at days 3, 7, and 11.
To evaluate the specificity of the effect of the CD19xCD3 DART 
molecule, we administered a control DART protein (4420xCD3), 
with one arm directed against an irrelevant target fluorescein, to 
BLT mice (n  =  4). We did not observe a decrease in the levels of 
human CD19+ B cells. An increase in the percentage of CD19+ lev-
els was noted 1 day after DART protein administration, but levels 
returned to normal by day 3 (Supplementary Figure S3).
We also measured the levels of human inflammatory cytokines 
(IL-1β, IL-6, IL-8, IL-10, IL-12p70, and TNF) in plasma samples from 
mice treated with vehicle, with control DART molecule, or with 
CD19xCD3 DART molecule (n = 4 each group). Before treatment, the 
levels of all cytokines tested were below the limit of quantitation 
(20 pg/ml) in all mice. One day after treatment, the levels remained 
below limit of quantitation in the mice treated with vehicle or con-
trol DART molecule. In contrast, 1 day after CD19xCD3 treatment, 
we noted a significant increase in the plasma levels of IL-6, IL-8, and 
IL-10: 337 ± 122 pg/ml IL-6, 528 ± 110 pg/ml IL-8, 1,800 ± 622 pg/ml 
IL-10 (mean  ±  SEM, P  <  0.0001 with two-way repeated-measures 
analysis of variance and Tukey’s multiple comparisons test). By three 
days after treatment, the cytokine levels in the CD19xCD3-treated 
mice decreased back to basal levels. Together, these results show 
(i) a transient increase in cytokine levels in response to CD19xCD3 
DART molecule treatment that resolves by 72 hours and (ii) the 
efficient and specific depletion of human CD19+ B cells from the 
peripheral blood of BLT humanized mice.
Depletion of human CD19+ B cells in tissues after administration of 
CD19xCD3 DART protein
In order to determine the systemic effects of the CD19xCD3 DART mol-
ecule, we harvested and isolated cells from the bone marrow, spleen, 
liver, and lung of the animals in the experiment described in Figure 1 
at day 11, and measured levels of human CD19+ B cells in each tissue. 
We observed a marked depletion of CD19+ cells in all the tissues ana-
lyzed of the CD19xCD3-treated animals, down to <0.1% (Figure 2a). 
In contrast, the percentages of CD19+ cells in the tissues from animals 
that received vehicle remained normal (61.6% ± 0.9 in the bone mar-
row, 48.3%± 1.0 in the spleen, 14.2% ± 1.6 in the liver, and 12.1% ± 0.6 
in the lung). The absolute numbers of CD19+ cells were reduced over 
2,100-fold in the bone marrow of the  CD19xCD3-treated animals and 
over 7,600-fold in the spleen, as compared to vehicle-treated ani-
mals. We could not detect CD19+ cells by flow cytometry in the livers 
and lungs of the mice that received the CD19xCD3 DART molecule 
(Figure  2b). These differences in CD19+ cell levels were statistically 
Figure 3 Immature human CD19+ B cells regenerate in NSG/BLT mice 
after CD19xCD3 DART protein administration. (a) Experimental outline. 
NSG/BLT mice were administered CD19xCD3 (n  =  3, 1 mg/kg i.v.) or 
vehicle (n = 3) at day 0 and day 7. Peripheral blood (PB) was collected 
and analyzed at days 0, 1, 3, 7, 14, 21, and 28; tissues were harvested 
and analyzed at day 28. (b) Percent CD19+ cells out of CD45+ cells and 
(c) number CD19+ cells per microliter detected in PB by flow cytometry 
(vehicle group in blue; CD19xCD3 group in red). (d) Percent CD19+ 
cells out of CD45+ cells and (e) number CD19+ cells detected in tissues 
by flow cytometry. (f) Percent immature CD10+ cells out of CD19+ cells 
detected in tissues by flow cytometry. (Mean ± SEM plotted. P values 
were calculated in b and c by repeated-measures two-way analysis of 
variance with Sidak’s multiple comparisons test, comparing vehicle 
versus CD19xCD3. P values were calculated in d–f by unpaired t-test, 
comparing vehicle versus CD19xCD3. ns, P > 0.05; *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001. Gray diamond indicates data from age-
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Figure 4 CD19xCD3 DART protein administration results in transient differences in the levels of human T cells in the peripheral blood of NSG/BLT mice, and 
over time there are no significant differences in absolute numbers of human CD8+ T cells in the peripheral blood or tissues as compared to vehicle-treated 
mice. NSG/BLT mice were administered CD19xCD3 (n = 3, 1 mg/kg i.v.) or vehicle (n = 3) at day 0 and day 7. Peripheral blood (PB) was collected and analyzed 
at days 0, 1, 3, 7, 14, 21, and 28; tissues were harvested and analyzed at day 28. (a) Percent CD45+ cells out of live cells and (b) number CD45+ cells per microliter 
detected in peripheral blood by flow cytometry (vehicle group in purple, CD19xCD3 group in brown). (c) Percent CD3+ cells out of CD45+ cells and (d) number 
CD3+ cells per microliter. (e) Percent CD8+ cells out of CD3+ cells and (f) number CD8+ cells per microliter. (g) Percent CD8+ cells out of CD3+ cells and (h) number 
CD8+ T cells detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in a–f by repeated-measures two-way analysis of variance 
with Sidak’s multiple comparisons test, comparing vehicle versus CD19xCD3. P values were calculated in g and h by unpaired t-test, comparing vehicle versus 
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significant between the vehicle group and the CD19xCD3-treated 
group across all tissues analyzed. Together, these results demonstrate 
that the CD19xCD3 DART molecule can effectively deplete human 
CD19+ B cells from tissues.
Regeneration of human CD19+ B cells after administration of 
CD19xCD3 DART protein
Next, we sought to investigate the durability of depletion as well 
as potential for regeneration of human CD19+ B cells after adminis-
tration of the CD19xCD3 DART molecule. We treated BLT mice with 
CD19xCD3 or vehicle (n = 3 for each group). We monitored the lev-
els of human CD19+ B cells in peripheral blood at days 1, 3, 7, 14, 21, 
and 28 after the first injection (Figure 3a).
As in the previous experiment in Figure  1b,c, we observed a 
depletion of CD19+ cells in the peripheral blood of the CD19xCD3-
treated animals over the first 2 weeks. At day 21 after the first 
injection, the levels of CD19+ cells in the peripheral blood began 
to increase in the CD19xCD3-treated group. By day 28, the differ-
ences in the levels of CD19+ cells were not statistically significant 
between the  vehicle-treated mice and the CD19xCD3-treated mice 
(Figure 3b,c). Analysis of the levels of CD19+ cells in the tissues at this 
time point were not significantly different between the animals that 
received vehicle versus CD19xCD3, indicating that regeneration of 
the B-cell population had occurred in the DART protein-treated ani-
mals (Figure 3d,e).
To confirm that the human CD19+ B cells that were present at 
day 28 in the CD19xCD3-treated animals were not residual from 
the pretreatment period, we assessed the developmental stage 
of the CD19+ cells appearing after CD19xCD3 administration. 
Specifically, we measured the levels of immature B cells as deter-
mined by human CD10 cell surface expression (gating scheme in 
Supplementary Figure S1b). The percentage of CD10+ cells out of 
the CD19+ population was significantly higher in the CD19xCD3-
treated mice across all tissues analyzed, reaching >90% in the bone 
marrow, spleen, and liver, and 80% in the lung (Figure  3f ). These 
results demonstrate the production of new B cells in mice previ-
ously treated with the CD19xCD3 DART protein.
Effect of CD19xCD3 DART protein administration on the levels of 
human T cells in vivo
To examine the effect of the CD19xCD3 DART molecule on human 
T cells in vivo, in particular CD8+ cytotoxic T cells, we measured the 
levels of human CD45+, CD3+, and CD8+ cells in peripheral blood 
after two administrations of vehicle or CD19xCD3 (1 mg/kg) 7 days 
apart, over a period of 4 weeks after the first administration.
Similar to the results presented above (Figure  1), we observed 
a sharp decline at day 1 of human CD45+ lymphocytes (both 
percentage and absolute number) in the peripheral blood of 
 CD19xCD3-treated animals (Figure 4a,b). However, this decline was 
only transient: by day 3, there was no longer a significant difference 
in the levels of human hematopoietic cells between the vehicle- 
and the CD19xCD3-treated mice. The levels were again significantly 
lower in the CD19xCD3-treated group at day 14 (7 days after the 
second administration), but there was not a significant difference 
at day 28.
With regard to T cells, we observed the same sharp decline at day 
1 in the percentage and absolute number of human CD3+ and CD8+ 
T cells in the peripheral blood. There followed an initial increase 
in the percent of CD3+ cells out of CD45+ cells on day 3 and day 7 
in the CD19xCD3-treated group, although this increase was not 
reflected in the absolute numbers of CD3+ cells per microliter of 
blood (Figure 4c,d). The percentages of CD8+ cells out of CD3+ cells 
were also higher in the CD19xCD3-treated animals on days 3, 7, and 
14. However, there was not a significant difference in the absolute 
Figure 5 Human CD8+ T cells are depleted after administration of CD8-depleting antibody. (a) Experimental outline. NSG/BLT mice were administered 
CD8-depleting antibody (CD8-depleted, n = 8, 3 mg/kg i.v.) or vehicle (CD8-intact, n = 7) 4 days prior to administration of CD19xCD3 DART protein 
to all mice (1 mg/kg i.v.). Peripheral blood (PB) was collected and analyzed at 4 days and 1 day prior to and at days 3, 7, and 14 after administration of 
CD19xCD3 DART protein; tissues were harvested and analyzed at day 15. (b) Percent CD8+ cells out of CD3+ cells and (c) number CD8+ cells per microliter 
detected in PB by flow cytometry (CD8-depleted in orange, CD8-intact in green). (d) Percent CD8+ cells out of CD3+ cells and (e) number CD8+ cells 
detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in b and c by repeated-measures two-way analysis of variance 
with Sidak’s multiple comparisons test, comparing CD8-depleted versus CD8-intact. P values were calculated in d and e by unpaired t-test, comparing 
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numbers of CD8+ cells at day 3 or day 7, and the CD19xCD3-treated 
animals had lower numbers of CD8+ cells on day 14 (Figure 4e,f ). By 
day 28, there were no significant differences between the groups in 
the percentages or absolute numbers of peripheral blood human 
CD45+, CD3+, or CD8+ cells.
At harvest on day 28, there was a small but statistically significant 
increase in the percentage of CD8+ cells out of CD3+ cells in the bone 
marrow and spleen of the CD19xCD3-treated animals: 18.2% ± 1.5 
(vehicle) versus 28.6% ± 1.8 (CD19xCD3) (P < 0.05) and 14.9% ± 1.3 
(vehicle) versus 19.7%  ±  0.5 (CD19xCD3) (P  <  0.01), respectively 
(Figure  4g). The percentages of CD8+ cells were not significantly 
different in the livers or the lungs of these mice. We observed no 
difference in the total number of CD8+ cells in any of the tissues ana-
lyzed (Figure  4h). These results demonstrate that exposure to the 
CD19xCD3 DART molecule does not have a significant effect on the 
levels of human CD8+ T cells in peripheral blood or tissues.
Dependence of CD19xCD3 DART protein-mediated depletion on 
the presence of human CD8+ T cells
To investigate the mechanism of action in vivo of the CD19xCD3 
DART molecule, we evaluated the necessity of human CD8+ T cells 
for target B-cell depletion. One group of BLT mice was administered 
a CD8-depleting antibody (anti-CD8α antibody MT807R1, kindly 
provided by Dr Guido Silvestri)39,40 i.v. at 3 mg/kg (CD8-depleted 
group, n  =  8), and one group was administered vehicle (normal 
saline, CD8-intact group, n = 7). Four days later, both groups were 
administered CD19xCD3 one time i.v. (1 mg/kg). Peripheral blood 
was collected and analyzed at 4 days and 1 day prior to and at days 
3, 7, and 14 after administration of CD19xCD3 DART protein; tissues 
were harvested and analyzed at day 15 (Figure 5a).
To confirm depletion of human CD8+ T cells, we measured the 
levels of CD8+ cells in the peripheral blood and tissues. By 3 days 
after administration of the CD8-depleting antibody (or 1 day prior 
to CD19xCD3 administration), the percentage of CD8+ cells out of 
CD3+ cells decreased to <0.3% ± 0.1, and the number of CD8+ cells 
decreased to 2 ± 0.7 CD8+ cells per microliter peripheral blood in 
the CD8-depleted group. The levels of CD8+ cells in the CD8-intact 
group were 19% CD8+ out of CD3+ and 528 CD8+ cells per microli-
ter at this time point (Figure 5b,c). In the tissues (harvested at day 
15 after CD19xCD3 administration), the percentages of CD8+ out of 
CD3+ were <1% in the bone marrow and <0.5% in the spleen, liver, 
and lung of the CD8-depleted mice (Figure 5d); the number of CD8+ 
cells were reduced 28-fold in the bone marrow, 89-fold in the spleen, 
186-fold in the liver, and 110-fold in the lung in the  CD8-depleted 
animals as compared to the CD8-intact group (Figure 5e).
Similar to previous experiments, the human CD19+ B cells were vir-
tually completely depleted in the peripheral blood of the  CD8-intact 
mice (Figure 6a,b). In contrast, in the CD8-depleted mice, we observed 
only a transient decline in the levels of CD19+ cells at day 3 followed 
by a recovery to near normal CD19+ levels by day 7. The differences 
in the levels of CD19+ cells between the CD8-intact animals and the 
CD8-depleted animals were statistically significant at days 7 and 14.
Consistent with the depletion of the human CD19+ B cells from the 
peripheral blood, the levels of CD19+ cells in the tissues were also sig-
nificantly reduced in the CD8-intact group as compared to the CD8-
depleted group (Figure  6c). Even though there was no difference 
between the groups in number of total bone marrow CD19+ cells, 
there was at least a 10-fold statistically significant reduction in the 
total number of CD19+ cells in the spleen, liver, and lung of the CD8-
intact versus CD8-depleted animals (Figure 6d). Together, these results 
Figure 6 Human CD19+ B-cell depletion by CD19xCD3 DART protein is dependent on the presence of human CD8+ T cells. NSG/BLT mice were 
administered CD8-depleting antibody (CD8-depleted, n = 8, 3 mg/kg i.v.) or vehicle (CD8-intact, n = 7) 4 days prior to administration of CD19xCD3 
DART protein to all mice (1 mg/kg i.v.). Peripheral blood (PB) was collected and analyzed at 4 days and 1 day prior to and at days 3, 7, and 14 after 
administration of CD19xCD3 DART protein; tissues were harvested and analyzed at day 15. (a) Percent CD19+ cells out of CD45+ cells and (b) number 
CD19+ cells per microliter detected in PB by flow cytometry (CD8-depleted in orange, CD8-intact in green). (c) Percent CD19+ cells out of CD45+ cells 
and (d) number CD19+ cells detected in tissues by flow cytometry. (Mean ± SEM plotted. P values were calculated in a and b by repeated-measures 
two-way analysis of variance with Sidak’s multiple comparisons test, comparing CD8-depleted vs. CD8-intact. P values were calculated in c and d by 
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demonstrate that the depletion of human CD19+ B cells by CD19xCD3 
DART molecule is dependent on the presence of human CD8+ T cells.
DISCUSSION
Building upon the success of monoclonal antibody therapies in the 
treatment of hematologic malignancies, novel strategies can still be 
useful toward improving cure rates. Bispecific molecules like DART 
molecules are promising in their ability to recruit T cells to kill target 
cells without the need for ex vivo expansion or MHC matching. The 
in vivo effects of T-cell–redirecting DART molecules have been eval-
uated in xenograft-bearing mice reconstituted with human PBMCs 
and in nonhuman primates, and several DART candidates are cur-
rently being evaluated in human clinical trials for oncology indica-
tions (NCT02152956, NCT02248805, NCT02454270).
Humanized BLT mice present an excellent preclinical model for 
the in vivo evaluation of CD19xCD3 DART molecules, as they harbor 
HLA-matched target and effector cells (human CD19+ B cells and 
human CD3+ T cells, respectively). BLT mice also allow us to assess 
(i) the extent of target cell depletion systemically, (ii) the effect on 
other relevant human hematopoietic cells, and (iii) the role of cyto-
toxic T cells after DART protein administration in vivo.
In our study, we observed a profound depletion of target human 
CD19+ B cells in both the peripheral blood and the tissues (bone 
marrow, spleen, liver, and lung) after two i.v. administrations of 1 mg/
kg CD19xCD3 (Figures 1d,e and 2a,b). This effect was specific to the 
CD19-targeting arm, as a fluorescein-directed 4420xCD3 DART mol-
ecule did not result in similar CD19+ cell depletion (Supplementary 
Figure S3).
CD19+ cells began to return in the peripheral blood of 
 CD19xCD3-treated BLT mice by day 21 after the first injection (or 
by day 14 after the second injection) (Figure  3b,c); and by day 
28, the levels of B cells were not significantly lower in the tissues 
of CD19xCD3-treated mice as compared to vehicle-treated mice 
(Figure 3d,e). A vast majority of the human CD19+ cells appearing 
in the tissues had an immature phenotype (Figure 3f,g), as indicated 
by CD10 staining, suggesting that the B cells present are the result 
of de novo generation and development rather than of homeostatic 
proliferation.
A recent report evaluating an anti-CD20/CD3 T cell-dependent 
bispecific antibody reported initial increases in human CD8+ T cell 
counts followed by decreases to baseline or lower in the periph-
eral blood and spleen of CD3ε/CD20-transgenic mice or NSG mice 
humanized by CD34+ cell transplant.41 We investigated the effect of 
the CD19xCD3 DART molecules on human lymphocytes and T cells 
in humanized BLT mice. Interestingly, we observed a transient 
decrease in virtually all the human lymphocytes in the peripheral 
blood on day 1 after the first injection (Figures 1b,c and 4a–f). This 
initial decline is followed by a recovery to near normal levels of the 
peripheral blood human lymphocytes by day 3, with the remark-
able absence of virtually all the B cells that had been depleted 
(Figure  1d,e). A similar transient lymphopenia has been observed 
in chimpanzees following administration of a bispecific anti-CD19/
anti-CD3 single-chain BiTE construct at 10 hours followed by recov-
ery at 24–72 hours.42 This transient lymphopenia could be explained 
by redistribution of lymphocytes that are adhering to blood ves-
sel walls or migrating into tissues. Despite temporary differences, 
peripheral blood human CD45+, CD3+, and CD8+ cell levels in the 
CD19xCD3 DART protein-treated animals returned to similar levels 
as the vehicle group by day 28 after the first injection (Figure 4a,f ). 
Notably, the number of human CD8+ T cells were not significantly 
different between the vehicle- and CD19xCD3 DART protein-treated 
animals in the bone marrow, spleen, liver, and lung (Figure 4h).
Finally, we evaluated the dependence of target human CD19+ 
B-cell depletion by CD19xCD3 DART molecules on the presence 
of human CD8+ T cells. BLT mice that were CD8-depleted prior to 
CD19xCD3 administration did not exhibit the reduction of CD19+ 
cells in the peripheral blood that was observed in CD8-intact ani-
mals (Figure  6b,c), and the CD8-depleted group had significantly 
higher systemic levels of CD19+ cells, except in the bone mar-
row (Figure 6d,e). These data suggest that human CD8+ T cells are 
required for depletion of human CD19+ B cells by CD19xCD3 DART 
molecules.
This study validates the humanized BLT mouse as a preclinical 
model for the use and evaluation of bispecific reagents, in particu-
lar DART molecules. The BLT mouse model provides opportunities 
to study the in vivo effects of bispecific molecules on human target 
cells both in the peripheral blood and the tissues. Future directions 
could include the evaluation of DART molecules directed against 
other target immune cells or against viral antigens expressed on 
infected cells. A recent paper from Sung et al.43 showed data on the 
efficacy ex vivo of a DART molecule directed against HIV envelope 
protein, thus providing a rationale for further in vivo studies in BLT 
humanized mice of DART molecules as a targeted cytotoxic therapy 
against HIV-infected cells, as we have previously demonstrated 
using an immunotoxin strategy.44
MATeRIAlS AND MeTHODS
Ethics statement
All animal experiments were conducted following NIH guidelines for hous-
ing and care of laboratory animals and in accordance with University of 
North Carolina at Chapel Hill (UNC Chapel Hill) regulations after review 
and approval by the UNC Chapel Hill Institutional Animal Care and Use 
Committee (permit number 12–171).
Generation of BLT humanized mice
BLT mice were generated as described previously.32 NOD/SCID-γ chain null 
mice (NSG, Stock #5557, The Jackson Laboratory, Bar Harbor, ME) were 
sublethally irradiated, implanted with human thymus and liver tissue, and 
transplanted with autologous human liver CD34+ cells (Advanced Bioscience 
Resources, Rockville, MD); then they were monitored for human reconstitu-
tion in peripheral blood by flow cytometry.25,28,32 All BLT mice (n = 31) used for 
these experiments contained an average of 63.5% ± 13.6 SD human CD45+ 
cells in the peripheral blood, of which 39% ± 9.3 SD expressed human CD19, 
and 53.3% ± 10.7 SD expressed CD3 on their cell surface. 78.3% ± 6.5 SD of 
human CD3+ cells expressed human CD4.
DART molecules
As described by Moore et al.,20 the CD19xCD3 DART molecule, in basic for-
mat, was constructed using anti-human CD19 Fv sequences from HD37 (ref. 
45) and anti-human CD3 Fv sequences from TR66 (refs. 38,46); and the irrel-
evant arm of the control DART molecule (4420xCD3) was constructed from 
 anti-fluorescein Fv sequences from 4-4-20 (ref. 47). The binding arms of this 
CD19xCD3 DART protein do not crossreact with murine antigens. The DART 
proteins were produced in CHO-S cells and purified as described.20
Treatment of BLT mice
BLT mice were injected intravenously with CD19xCD3 DART molecule 
(MacroGenics, Rockville, MD) at a dose of 1 mg/kg either one time or two 
times 7 days apart, with 4420xCD3 DART molecule at a dose of 1 mg/kg 
two times 7 days apart, or with vehicle (normal saline, 0.9% sodium chlo-
ride, #0409-4888-10, Hospira, Lake Forest, IL). For CD8+ T-cell depletion, BLT 
mice were injected i.v. with CD8-depleting antibody (anti-CD8α antibody 
MT807R1, gift from Dr Guido Silvestri, Atlanta, GA) at a dose of 3 mg/kg or 
with vehicle (normal saline).
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Analysis of BLT mice
Peripheral blood and tissues were collected and cells isolated as previously 
described for flow cytometric analysis.25,28 Antibodies used in these experi-
ments included anti-human CD45 APC (clone HI30, catalog #555485), CD45 
FITC (2D1, 347463), CD3 FITC (HIT3a, 555339), CD8 APC-Cy7 (SK1, 557834), 
CD8 PerCP (SK1, 347314), CD19 PE-Cy7 (SJ25C1, 557835), CD10 APC (HI10a, 
340923) (BD Biosciences, San Jose, CA). Flow cytometry data were acquired 
using a BD FACSCanto Cytometer and analyzed using BD FACSDiva software 
(version 6.1.3) with the following gating strategy: live cells → human CD45+ → 
human CD19+ (→ human CD10+) or live → human CD45+ → human CD3+ → 
human CD8+. The numbers of cells per microliter peripheral blood were cal-
culated by dividing the number of positive events acquired by the number of 
microliters of peripheral blood stained. The numbers of cells per tissue were 
calculated by multiplying the total number of live cells isolated from the tis-
sue, by the fraction of positive events over live events. Cytokine analysis was 
performed on plasma samples using a Human Inflammatory Cytokine Kit 
(551811, BD Biosciences, San Jose, CA); these data were acquired using a BD 
LSR II Cytometer and analyzed using FCAP Array Infinite (Soft Flow, St Louis 
Park, MN).
Statistical analysis
All statistical tests were performed with an alpha level of 0.05. 
 Repeated-measures two-way analysis of variance with Sidak’s multiple 
comparisons test was used to generate the P values in Figures  1b–e, 
3b,c, 4a–f, 5b,c, and 6a,b. Unpaired t-test was utilized to generate the 
P values in Figures 2, 3d,f, 4g,h, 5d,e, and 6c,d. Graphs were generated in 
Graphpad Prism (version 6).
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